Clinical Trial: Phase II Study of Combined Pirtobrutinib, Venetoclax and Obinutuzumab (PVO) Time-limited Treatment for Patients With Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL).

U.S., May 14 -- ClinicalTrials.gov registry received information related to the study (NCT06967610) titled 'Phase II Study of Combined Pirtobrutinib, Venetoclax and Obinutuzumab (PVO) Time-limited Treatment for Patients With Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL).' on May 05.

Brief Summary: To learn if the drug combination pirtobrutinib, venetoclax, and obinutuzumab can help to control relapsed CLL/SLL.

Study Start Date: Oct. 30, 2025

Study Type: INTERVENTIONAL

Condition: Chronic Lymphocytic Leukemia Small Lymphocytic Leukemia (SLL)

Intervention: DRUG: Pirtobrutinib

Given PO 200mg daily

DRUG: Venetoclax

Given PO daily

DRUG: Obinutuzumab

Given IV 100mg day 1, 900 mg day 2, 100mg days 8, 15

Re...